e-SPACE Cardio-Renal-Metabolic 2024
Published: 29 March 2024
-
Views:
432 -
Likes:
7
-
Views:
432 -
Likes:
7
-
Up Next
-
1h 10s
-
1h 8m 49sPart 2 | Session 4 Plenary Session 8 – Early intervention and intensive management
-
27m 17sPart 2 | Session 5 Effects of GLP- 1RA on kidney outcomes in CKD and T2D
-
1h 3m 47sPart 2 | Session 6 Plenary Session 9 – Precision medicine in CRM
-
1h 6sPart 1 | Session 1 Plenary Session 1 – Multidisciplinary implementation strategies Gerasimos Filippatos, Manisha Sahay, Gianluigi Savarese, Francesco Cosentino, Sam Seidu
-
28m 56sPart 1 | Session 2 Keynote Session – KDIGO guideline updates 2024 Paul Stevens
-
1h 2m 27sPart 1 | Session 3 Plenary Session 2 – Guideline directed therapy for CRM disease: the evidence base Intissar Haddiya, Lars H Lund, Marco Metra, Nikolaus Marx, Peter Rossing, Giuseppe Rosano
-
59m 47sPart 1 | Session 4 Plenary Session 3 – Managing the patients with CRM: who gets what, when and why? Gianluigi Savarese, Alice Cheng, Adeera Levin, Antonio Ceriello, Shelley Zieroth, Giuseppe Rosano
-
57m 21sPart 1 | Session 5 Plenary Session 4 – Weight homeostasis management in CRM disease (Organised with support from Charité Friends & Sponsors Trust) Scott Isaacs, Peter Rossing, Muthiah Vaduganathan, Stefan Anker, Javed Butler
-
1h 7sPart 1 | Session 6 Plenary Session 5 – CRM disease: epidemiology and pathophysiology Ahmed Bennis, Ileana L Piña, Giulia Ferrannini, Chiadi Ndumele, Rodica Pop-Busui, Mitja Lainscak
-
54m 56sPart 2 | Session 1 Plenary Session 6 – Anaemia and iron deficiency John GF Cleland, Gerasimos Filippatos, Ewa Jankowska, David Wheeler, Kieran Docherty
Overview
KDIGO and Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Cardio-Renal-Metabolic (CRM) 2024.
A thoughtfully curated programme supported the exploration of how leading experts, in cardiology, nephrology and diabetology, treat the interrelated diseases.
This event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Related sessions to e-SPACE Cardio-Renal-Metabolic 2024:
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease and obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
David Charytan
Nephrologist
Dr David Charytan is a Nephrologist at NYU Langone Health, New York, US.
Dr Charytan's expertise is in caring for those with systemic lupus erythematous and other autoimmune kidney diseases, diabetic nephropathy and cardiorenal disease.
Comments